{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective from the specified list.", "method": "llm_batch", "batch_id": "batch_1_19856", "batch_size": 200, "batch_pos": 107, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "'climbed' describes stock price movement, a background condition, not the threat's impact.", "method": "llm_batch", "batch_id": "batch_2_15072", "batch_size": 200, "batch_pos": 88, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "'climbed 2.4%' is a financial metric, which is excluded from this rule.", "method": "llm_batch", "batch_id": "batch_3_8472", "batch_size": 200, "batch_pos": 24, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_6604", "batch_size": 200, "batch_pos": 21, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports stock movement and potential funding but contains no explicit calming cues.", "method": "llm_batch", "batch_id": "batch_5_9376", "batch_size": 200, "batch_pos": 18, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "The segment mentions shares climbed and funding but does not use a minimiser or scale contrast for reassurance.", "method": "llm_batch", "batch_id": "batch_6_8760", "batch_size": 200, "batch_pos": 180, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "The segment states a fact (stock price/deal) but contains no bare negation or explicit calming cue.", "method": "llm_batch", "batch_id": "batch_7_18348", "batch_size": 200, "batch_pos": 168, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "The segment describes a report that the U.S. government 'is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine', indicating funding for development of a future capability, without explicit calming keywords.", "method": "llm_batch", "batch_id": "batch_8_216", "batch_size": 200, "batch_pos": 129, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
